JP2009263294A - Agent for supressing/treating ulcer - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an agent for suppressing/treating ulcer, achieving further excellent effects on mucosa protection and ulcer curing compared to conventional agents for suppressing/treating ulcer such as zinc compounds and aluminum hydroxide; and a method for producing the same. <P>SOLUTION: The effects on suppressing/treating ulcer are increased by making synergistic actions of zinc with an aluminum compound develop through forming a solid solution of zinc having ulcer-curing action in an aluminum compound having high antacid power, or through uniformly incorporating zinc in a form so that the aluminum compound forms a coprecipitate with a zinc salt. <P>COPYRIGHT: (C)2010,JPO&amp;INPIT

Description

  The present invention relates to an ulcer suppressing / treating agent containing an aluminum compound (hereinafter, zinc-containing aluminum compound) containing zinc as a solid solution or forming a coprecipitate with a zinc salt as an active ingredient. More specifically, the present invention relates to an ulcer suppressing / treating agent comprising a zinc-containing aluminum compound as an active ingredient, which has a far superior effect compared to conventional ulcer suppressing / treating agents such as zinc compounds and aluminum hydroxide.

It is well known that zinc binds to mucosal proteins to form a coating that protects and restores damaged tissue cells.
Non-patent document 1 describes zinc compounds such as zinc sulfate and L-carnosine zinc complex as ulcer treatment agents utilizing this action. In particular, the latter is useful as an agent for suppressing or treating gastric ulcer because it has not only a mucosal protective action but also an antacid action.

Patent Document 1 discloses a pharmaceutical composition containing aluminum oxide hydrate as a main component and containing “trace amount” of zinc.
However, the pharmaceutical composition disclosed in Patent Document 1 is composed of a powder obtained by pulverizing natural inorganic minerals, and the zinc content determined from the description in the examples is 0.42% or less.
Therefore, it cannot be said that the pharmaceutical composition disclosed in Patent Document 1 actively utilizes the ulcer treatment effect of zinc, and it is considered that such an effect is not seen from the viewpoint of the zinc content.

In paragraph 0002 of Patent Document 2, it is described that “a preparation containing aluminum hydroxide and magnesium hydroxide has an antacid action and a gastric mucosa protective action”. Examples of acid agents are shown.

Patent Document 3 discloses a suppressive or therapeutic agent for peptic ulcer containing aluminosilicate holding silver ions and zinc ions.
Test Example 2 of Example of Patent Document 3 Table 2 shows that aluminosilicate containing 12.5% zinc ion was orally administered twice a day at a dose of 150 mg / kg (body weight), and the ulcer area was It is described that the inhibition rate was 56.8% with respect to the reference.
Masahiro Takatani, Tetsuya Inagaki, “Explanation of Medicine: Anti-ulcer Drug-L-carnosine Zinc Complex / Polaprezin”, Pharmacia, Japan Pharmaceutical Association, 1995, Vol. 31, No. 6, p. 613-615 JP 61-225126 A JP-A-9-143080 JP 2001-151681 A

An object of the present invention is to provide an ulcer suppressing / treating agent having a far superior effect compared to conventional ulcer suppressing / treating agents such as zinc compounds and aluminum hydroxide.

The ulcer treatment agents such as zinc sulfate and L-carnosine zinc complex described in Non-Patent Document 1 have sufficient mucosal protective action but maintain antacid power, that is, maintain gastric pH at 4-5 for a long time with a small amount. Insufficient ability to do so, there was a problem as a gastric ulcer suppression / treatment agent, especially the need to use antacids together.

In the peptic ulcer control / treatment drug of Patent Document 3, in order to obtain the effects shown in Test Example 2 Table 2, an adult having a body weight of 60 kg must take 1 g or more of zinc per day. . This is an intake that greatly exceeds the upper limit of 15 mg indicated by the Ministry of Health, Labor and Welfare, and such excessive intake of zinc may inhibit copper absorption.

In order to solve the above problem, the present inventor made a solid solution of zinc having an ulcer treatment action in an aluminum compound having a large antacid power, or formed a coprecipitate with a zinc salt to synergize zinc and the aluminum compound. It was found that by exhibiting the effect, an ulcer suppressing / treating agent having a far superior effect compared with conventional ulcer treating agents such as zinc compounds and aluminum hydroxide was obtained, and the present invention was completed.

The aluminum compound in the present invention is selected on the basis of its high antacid power. Preferably, a group consisting of dry aluminum hydroxide gel, dihydroxyaluminum aminoacetate, aluminum hydroxide / sodium bicarbonate coprecipitate, synthetic aluminum silicate, magnesium magnesium aluminate, magnesium aluminate metasilicate, and sucrose sulfate aluminum salt One type should be selected from the above, but a plurality of types may be combined if necessary.
In terms of antacid power, it is more preferable to use dry aluminum hydroxide gel, dihydroxyaluminum aminoacetate, aluminum hydroxide / sodium hydrogen carbonate coprecipitate, synthetic aluminum silicate, and alumina magnesium hydroxide.

The zinc-containing aluminum compound of the present invention in which zinc is uniformly contained in a form in which zinc is dissolved in the aluminum compound or the aluminum compound and zinc salt form a coprecipitate, serves as an antacid, It is considered that the aluminum compound adsorbs phytic acid, which inhibits the absorption of zinc in the body, and therefore has an excellent ulcer suppressing / treating effect.

When synthesizing the zinc-containing aluminum compound of the present invention, it is common to add a water-soluble zinc salt to a water-soluble aluminum salt as a raw material and prepare a mixed aqueous solution of the aluminum salt and the zinc salt in advance. .
The specific manufacturing method of each said zinc-containing aluminum compound is explained in full detail in an Example.

The water-soluble zinc salt serving as the zinc source may be any compound that generates zinc oxide or hydroxide by hydrolysis. Illustrative examples include zinc sulfate, zinc chloride, zinc nitrate, zinc acetate and zinc citrate.

In the zinc-containing aluminum compound of the present invention, the zinc content is preferably in the range of 0.05 to 10% by weight in terms of metallic zinc, from the viewpoint of sustainability of the effect and stability of the preparation, and more preferably 0. 0.05 to 2% by weight, most preferably 0.1 to 0.5% by weight.
If the zinc content exceeds 10% by weight, the antacid power may decrease.
On the other hand, when the zinc content is less than 0.05% by weight, the persistence of ulcer suppression / treatment effect may be reduced. However, depending on the administration interval, the effect of the present invention can be obtained even if the zinc content is less than 0.05% by weight.

It is important that zinc is dissolved in the aluminum compound or contained uniformly in a form that forms a coprecipitate with the aluminum compound. That is, the effect of the present invention cannot be obtained with a mixture obtained by mixing a zinc compound such as zinc chloride and aluminum hydroxide by a usual method.
However, in the aluminum compound particles, the effect of the present invention is not diminished even if zinc is ubiquitously dissolved on the surface.

The oral dosage when the zinc-containing aluminum compound of the present invention is used as an agent for suppressing or treating ulcer may be appropriately adjusted according to the patient's symptoms in the range of usually 100 to 10,000 mg / day per adult.

When the zinc-containing aluminum compound of the present invention is used as an agent for suppressing or treating ulcers, the dosage form may be any of powders, granules, tablets, pills, capsules, liquids for internal use, etc. , Binders, disintegrants and lubricants can be added.
Excipients include lactose, starch, crystalline cellulose, mannitol and calcium carbonate. Further, as a lubricant, there may be used usually used additives such as magnesium stearate, talc and macrogol as a lubricant.
When adjusting a liquid agent, the normal adjustment method which disperse | distributes preservatives, such as sodium benzoate, a pH adjuster, sweeteners, such as malic acid, and a fragrance | flavor other than the zinc-containing aluminum compound of this invention to purified water, is used.

As the granulation conditions and tableting conditions for producing the granules or tablets, the well-known conditions of each aluminum compound not containing zinc may be applied almost as they are. For example, tableting conditions for zinc-containing dry aluminum hydroxide gel can be found without undue trial and error based on known tableting conditions for dry aluminum hydroxide gel that does not contain zinc.

Thus, according to the present invention, an ulcer suppressing / treating agent comprising a zinc-containing aluminum compound as an active ingredient is provided as follows.
(1) A group consisting of dried aluminum hydroxide gel, dihydroxyaluminum aminoacetate, aluminum hydroxide / sodium bicarbonate coprecipitate, synthetic aluminum silicate, magnesium magnesium aluminate, magnesium aluminate metasilicate and sucrose sulfate aluminum salt An ulcer suppressing / treating agent comprising at least one aluminum compound selected from the group consisting of zinc as a solid solution or an active ingredient comprising a zinc-containing aluminum compound that forms a coprecipitate with a zinc salt .
(2) The ulcer inhibiting / treating agent according to (1) above, wherein the zinc content in the zinc-containing aluminum compound is in the range of 0.05 to 10% by weight.
(3) The ulcer inhibiting / treating agent according to (1), wherein the aluminum compound is dry aluminum hydroxide gel, dihydroxyaluminum aminoacetate, aluminum hydroxide / sodium hydrogencarbonate coprecipitate, synthetic aluminum silicate, and magnesium aluminate hydroxide. .
(4) A granule obtained by granulating the ulcer inhibiting / treating agent of (1).
(5) A liquid obtained by dispersing the ulcer inhibiting / treating agent of (1) in a liquid dispersion medium.
(6) A tablet obtained by tableting the ulcer inhibiting / treating agent of (1).

The present invention will be described in more detail based on examples.
Unless otherwise specified, reagent grade 1 manufactured by Wako Pure Chemical Industries, Ltd. was used.
The apparatus and method used in the examples are as follows.
(1) Component analysis MgO, Al ₂ O ₃ : by chelate titration method Zn: by atomic absorption method All zinc contents in the examples are values in terms of weight% in terms of metallic zinc.
(2) Measurement of antacid power The antacid power was measured by the antacid test method defined in the 14th revision Japanese Pharmacopoeia.
(3) Analysis of particle structure; X-ray diffraction analysis method: Cu-Kα, angle (2θ): 5 to 65 °, step: 0.02 °, scan speed: 4 ° / min, tube voltage: 40 kV Tube current: 20 mV.
Apparatus: RINT2200V X-ray diffraction system (manufactured by Rigaku Corporation)

(Synthesis Example 1) Synthesis of zinc-containing dry aluminum hydroxide gel To 1.05 mol / L aluminum sulfate aqueous solution, zinc sulfate heptahydrate was added in an amount of molar ratio Zn / aluminum sulfate = 0.029 and dissolved by stirring. (Hereinafter referred to as Zn-Al mixed solution 1)
In a 2.1 L stainless steel reaction vessel with overflow, 500 mL of tap water was previously added, and with stirring, a Zn-Al mixed solution of 12.5 mL / min and a 0.75 mol / L sodium carbonate aqueous solution at a flow rate of 57.5 mL / min Then, each was simultaneously fed using a metering pump and reacted for 5 hours. The reaction temperature was 25 ° C. ± 1 ° C., and the reaction pH was 6.5 to 6.6. The obtained reaction suspension was washed with Nucci under reduced pressure, dehydrated, dried at 70 ° C. for 20 hours, and pulverized with a lab scale hammer mill to obtain zinc-containing aluminum hydroxide gel particles.
The obtained aluminum hydroxide gel particles had an antacid power of 320 mL, and as a result of component analysis, the aluminum oxide contained 54.3% by weight and Zn contained 0.9% by weight.
An X-ray diffraction pattern of the zinc-containing aluminum hydroxide gel particles is shown in FIG. As is apparent from FIG. 1, the zinc-containing aluminum hydroxide gel particles are an amorphous compound. Since zinc compounds are not manifested on the X-ray diffraction pattern, most zinc is dissolved in aluminum hydroxide gel or forms an amorphous coprecipitate with aluminum hydroxide. Inferred.
(Synthesis Example 2) Synthesis of zinc-containing dihydroxyaluminum aminoacetate 500 mL of tap water and 130 g of zinc-containing aluminum hydroxide gel particles obtained in Synthesis Example 1 were placed in a 1 L beaker to prepare a zinc-containing aluminum hydroxide gel suspension. did. Subsequently, 104 g of glycine (manufactured by Showa Denko KK) was added under stirring and the temperature was raised to 85 ° C., followed by aging at 85 ° C. ± 1 ° C. for 1 hour. After cooling, it was dried using a lab scale spray dryer to obtain zinc-containing dihydroxyaluminum aminoacetate particles. The obtained zinc-containing dihydroxyaluminum aminoacetate particles had an antacid power (in terms of dry matter) of 201 mL. As a result of component analysis, aluminum oxide (dry matter) was 37.1% by weight, nitrogen (dry matter) was 10.1% by weight, and the Zn content was 0.54% by weight.
(Synthesis Example 3) Synthesis of zinc-containing aluminum hydroxide / sodium bicarbonate coprecipitate In a 1 L beaker, 800 mL of tap water and 115 g of the zinc-containing aluminum hydroxide gel particles obtained in Synthesis Example 1 were placed, and zinc-containing hydroxide was added. An aluminum gel suspension was prepared. Subsequently, 85 g of reagent-grade sodium bicarbonate was added under stirring and the temperature was raised to 70 ° C., followed by aging at 70 ° C. ± 1 ° C. for 1 hour. After cooling, it was washed under reduced pressure with Nuccie, dehydrated, dried at 70 ° C. for 20 hours, and pulverized with a lab scale hammer mill to obtain zinc-containing aluminum hydroxide / sodium hydrogen carbonate coprecipitate particles.
Further, the antacid power (in terms of dry matter) of the obtained zinc-containing aluminum hydroxide / sodium hydrogen carbonate coprecipitate particles was 280 mL. As a result of component analysis, aluminum (in terms of dry matter) was 19.3% by weight, sodium (in terms of dry matter) was 14.7% by weight, and the Zn content was 0.53% by weight.
(Synthesis Example 4) Synthesis of zinc-containing aluminum silicate Zinc sulfate heptahydrate was added to a 0.16 mol / L aluminum sulfate aqueous solution in an amount of molar ratio Zn / aluminum sulfate = 0.032 and dissolved by stirring. (Hereinafter referred to as “fallen Zn—Al mixture 2”)
Further, tap water was added to No. 3 sodium silicate aqueous solution to prepare No. 3 sodium silicate aqueous solution having a SiO ₂ concentration of 1.67 mol / L.
In a 2.1 L stainless steel reaction vessel with overflow, 500 mL of tap water was previously added, and 36.6 mL / min of the Zn-Al mixed solution 2 and 3 sodium silicate aqueous solution at a flow rate of 33.4 mL / min with stirring. Each was supplied simultaneously using a metering pump and reacted for 5 hours. The reaction temperature at this time was 25 ° C. ± 1 ° C., and the reaction pH was 4.0 to 4.2.
The obtained reaction suspension is aged at 70 ° C. ± 1 ° C. for 1 hour, cooled, washed under reduced pressure with Nuccie, dehydrated, dried at 70 ° C. for 20 hours, pulverized with a lab scale hammer mill, and synthesized with zinc Obtained aluminum silicate particles.
Further, the antacid power of the obtained zinc-containing synthetic aluminum silicate particles was 65 mL. As a result of component analysis, the Zn content was 0.61% by weight.
Synthesis Example 5 Synthesis of Zinc-Containing Alumina Magnesium Hydroxide Zinc sulfate heptahydrate was added to 1.05 mol / L aluminum sulfate aqueous solution in an amount of molar ratio Zn / aluminum sulfate = 0.4 and dissolved by stirring. (Hereinafter referred to as Zn-Al mixture 3)
In a 3.5 L stainless steel round tank, 1 L of tap water and 87.5 g of magnesium hydroxide (trade name: Kisuma / Kyowa Chemical Industry Co., Ltd.) are put, and Zn-Al mixed solution 3 520 mL and 0.75 mol are added with stirring. 1,670 mL of / L sodium carbonate aqueous solution was simultaneously added in 30 minutes using each metering pump. The reaction temperature at this time was 25 ° C. ± 1 ° C., and the pH of the solution at the end of the reaction was 7.9. The obtained reaction suspension was washed with a Nuccie under reduced pressure, dehydrated, dried at 80 ° C. for 20 hours, and pulverized with a lab scale hammer mill to obtain zinc-containing alumina magnesium hydroxide particles.
The antacid power of the obtained zinc-containing alumina magnesium hydroxide was 312 mL. As a result of component analysis, aluminum oxide was 21.7% by weight and magnesium oxide was 30.0% by weight. The Zn content was 8% by weight.
(Synthesis Example 6) Synthesis of Zinc-Containing Dry Aluminum Hydroxide Gel Synthesis was performed in the same manner as in Synthesis Example 1 except that zinc sulfate heptahydrate was not added to obtain dry aluminum hydroxide gel particles.
In a 200 mL beaker, 50 mL of ion exchange water and 10 g of the dry aluminum hydroxide gel were added and stirred at 40 ° C. When suspended, 0.2 g of zinc chloride was added and the mixture was further stirred for 1 hour. The obtained suspension was washed with Nuccie under reduced pressure, dehydrated, dried at 80 ° C. for 1 hour and pulverized to obtain zinc-containing alumina magnesium hydroxide particles.
The obtained aluminum hydroxide gel particles had an antacid power of 320 mL and contained 0.9% by weight of Zn as a result of component analysis.
(Synthesis Example 7) Synthesis of zinc-containing magnesium aluminate metasilicate In a 6-L stainless steel reaction vessel, 1.1 mol of 1 mol / L aluminum chloride aqueous solution and zinc sulfate heptahydrate become atomic ratio Zn / Al = 0.19. Add the amount and dissolve with stirring. Furthermore, this aqueous solution was heated to 75 ° C., and under stirring, 3.65 mol / L3 sodium silicate (molar ratio SiO ₂ / Na ₂ O = 3.13, SiO ₂ content 27.0%) 1.42 L After the addition, the mixture is further stirred at 75 ° C. for 1 hour (ripening). After cooling to 50 ° C., 1.75 mol / L magnesium chloride 1 L and sodium aluminate (molar ratio Na ₂ O / Al ₂ O ₃ = 1.5, Al ₂ O ₃ content 22%) 920 g and 0.267 mol / 1 L of L potassium hydroxide was added simultaneously in 30 minutes using each metering pump.
Thereafter, the mixture was further stirred at 50 ° C. for 1 hour (ripened). The final reaction solution had a pH of 10.3. The obtained reaction suspension was washed under reduced pressure, dehydrated, dried at 70 ° C. for 20 hours using a laboratory hot air dryer, and pulverized with a laboratory scale hammer mill to obtain zinc-containing magnesium aluminate metasilicate particles. Chemical analysis values of the obtained zinc-containing magnesium aluminate metasilicate particles were: aluminum oxide content = 28.1 wt%, magnesium oxide content = 11.1 wt%, silicon dioxide content = 32.2 wt%, The zinc content (Zn) was 1.2% by weight and the antacid power was 225 mL.
(Synthesis Example 8) Synthesis of zinc-containing sucrose polysulfate aluminum Aluminum zinc sulfate heptahydrate was added to a 0.5 mol / L aluminum sulfate aqueous solution in an amount of molar ratio Zn / aluminum sulfate = 0.005 and dissolved with stirring. (Hereinafter referred to as Zn-Al mixed solution 5)
Moreover, 50 g of sucrose polysulfate sodium salt was added to 1 L of tap water and dissolved to prepare a sucrose polysulfate sodium salt solution.
While stirring 520 mL of the Zn-Al mixed solution 5 in a 3.5 L stainless steel round tank, the sucrose polysulfate sodium salt solution was added dropwise with stirring. At this time, the pH of the reaction solution was adjusted to 5.
About 1 hour after the start of the reaction, the obtained reaction suspension was washed with Nutsie under reduced pressure, dehydrated, dried at 80 ° C. for 20 hours, pulverized with a lab scale hammer mill, and zinc-containing sucrose sulfate aluminum I got particles.
The antacid power of the obtained zinc-containing sucrose sulfate aluminum was 50 mL. As a result of component analysis, aluminum oxide was 34.5% by weight and sulfur was 10.3% by weight. The Zn content was 0.1% by weight.
(Comparative Example 1) Preparation of a mixture of zinc chloride and dry aluminum hydroxide gel Synthesis was performed in the same manner as in Synthesis Example 1 except that zinc sulfate heptahydrate was not added to obtain dry aluminum hydroxide gel particles. . To 10 g of dry aluminum hydroxide gel, 0.19 g of zinc chloride was added and mixed.
The antacid power of the obtained zinc-containing alumina magnesium hydroxide (zinc content 0.9% by weight) was 320 mL.

Ethanol-induced gastric mucosal damage tests were performed on the zinc-containing aluminum compounds of each synthesis example obtained in Example 1 and commercially available anti-ulcer drugs using male SPF rats.
As a commercially available anti-ulcer drug, a powder obtained by grinding an L-carnosine zinc complex (trade name: Promac / Zeria Shinyaku Kogyo Co., Ltd.—zinc content: 34 mg / g) in a mortar, 0.5% methylcellulose as a control A purified water suspension of was used.

A solution was prepared by suspending 1 g of each zinc-containing aluminum compound of each synthesis example obtained in Example 1, 1 g of the mixture of Comparative Example 1 and 295 mg of L-carnosine zinc complex powder in 100 mL of purified water.
The above-mentioned solutions and controls were orally administered at 10 mL / kg (body weight) to SPF rats (n = 6 / body weight about 200 g) fasted for 24 hours. One hour later, 10 mL / kg (body weight) of absolute ethanol was orally administered.
One hour later, the stomach was removed, 10 mL of 1% formalin solution was injected into the removed stomach and immersed in the same solution for 10 minutes or more. The stomach was incised along a large bay, and the total length of damage occurring per animal observed with a stereomicroscope was defined as the “damage factor”.
In addition, the value of each damage coefficient relative to the control was defined as “inhibition rate%”.
The results of evaluating the degree of gastric mucosal disorder inhibiting effect are shown in Table 1.

As is apparent from Table 1, the zinc-containing aluminum compound of the present invention has a gastric mucosal protective action, that is, an ulcer inhibitory action as compared with a conventionally known anti-ulcer drug and a conventionally known mixture of an antacid and zinc sulfate. Significant difference was shown.
In Table 1, since the zinc-containing aluminum compound of the present invention shows a large inhibition rate against the ulcer suppressing effect exhibited by the mixture of zinc chloride and dry aluminum hydroxide gel of Comparative Example 1, zinc is either a solid solution or water. By forming an amorphous coprecipitate with aluminum oxide, an effect not seen in the mixture is obtained.

The same solution and control as in Example 2 were prepared.
Male SPF rats were orally administered with 1 mL of 99.5% ethanol to cause gastric ulcers. Each solution was orally administered twice daily (9:30 am and 5:30 pm) for 2 weeks from the day after the occurrence of gastric ulcer (5 mL / kg (body weight)). Feed was continued twice daily at 9:00 am and 5:00 pm from 3 days before gastric ulcer development. The stomach was excised on the 15th day after the occurrence of the gastric ulcer, and the total length of damage occurring per mouse observed with a stereomicroscope was defined as the “damage factor”.
In addition, the value of each damage coefficient relative to the control was defined as “inhibition rate%”.
Table 2 shows the results of evaluating the effect of promoting ulcer healing. Table 2 shows the results of evaluating the degree of gastric mucosal disorder healing promoting effect.

As is apparent from Table 2, the zinc-containing aluminum compound of the present invention has an ulcer healing-promoting effect, that is, an ulcer treatment effect as compared with a conventionally known anti-ulcer drug and a conventionally known mixture of an antacid and zinc sulfate. Significant difference was shown.
Moreover, in Table 2, since the zinc-containing aluminum compound of the present invention shows a large healing rate with respect to the ulcer treatment effect exhibited by the mixture of zinc chloride and dry aluminum hydroxide gel of Comparative Example 1, zinc was dissolved in a solid solution. By forming an amorphous coprecipitate with aluminum hydroxide, an effect not seen in the mixture is obtained.

By the method of the present invention, an ulcer suppressing / treating agent having a far superior effect as compared with conventional ulcer suppressing / treating agents such as zinc compounds and aluminum hydroxide can be provided.

1 is an X-ray diffraction pattern of a zinc-containing dry aluminum hydroxide gel obtained in Synthesis Example 1 of Example 1. FIG.

Claims (6)

Selected from the group consisting of dry aluminum hydroxide gel, dihydroxyaluminum aminoacetate, aluminum hydroxide / sodium hydrogen carbonate coprecipitate, synthetic aluminum silicate, magnesium alumina hydroxide, magnesium aluminate metasilicate, and sucrose sulfate aluminum salt An ulcer suppressing / treating agent comprising, as an active ingredient, at least one kind of aluminum compound, wherein the aluminum compound contains zinc as a solid solution or forms a coprecipitate with a zinc salt. The ulcer suppressing / treating agent according to claim 1, wherein the zinc content in the zinc-containing aluminum compound is in the range of 0.05 to 10% by weight in terms of metallic zinc. The ulcer suppressing / treating agent according to claim 1, wherein the aluminum compound is dry aluminum hydroxide gel, dihydroxyaluminum aminoacetate, aluminum hydroxide / sodium hydrogencarbonate coprecipitate, synthetic aluminum silicate, and magnesium aluminate hydroxide. A granule obtained by granulating the ulcer suppressing / treating agent according to claim 1. The liquid agent obtained by disperse | distributing the ulcer inhibitory / therapeutic agent of Claim 1 to a liquid dispersion medium. A tablet obtained by tableting the ulcer suppressing / treating agent according to claim 1.

Images